The first 240 packages of the anti-Covid pill are distributed in Friuli Venezia Giulia

UDINE. There are a total of 240 packs of the antiviral Molnupinavir to be sent to Friuli Venezia Giulia for the outpatient treatment of Covid-19 in cases with specific risk factors.

This was announced by the deputy governor with responsibility for Health Riccardo Riccardi, specifying that the treatments have been available since yesterday and are divided as follows between the three companies: 106 packs for the Friuli Centrale university healthcare company (Asufc), 72 packs for the healthcare company Giuliano Isontina University (Asugi) and 62 for the Western Friuli Health Authority (Asfo).

The pharmaceutical product is active against the rna polymerase of numerous rna viruses, including Sars-CoV2, and its administration must take place as early as possible with respect to the onset of symptoms and in any case no later than five days from their onset. .

Aifa has authorized the drug in non-hospitalized adults, with mild-moderate disease, of recent onset and with concomitant clinical conditions that represent specific risk factors for the development of severe Covid-19: oncological / oncohematological pathology in active phase, chronic renal failure , severe pulmonary disease, primary or acquired immunodeficiency, obesity, severe cerebrocardiovascular disease, uncompensated diabetes and chronic liver disease.

As Riccardi recalled, a recent study with Molnupinavir

800 mg administered every 12 hours for 5 days to patients with outpatient Covid-19 disease, not on oxygen therapy, with symptoms for less than five days and with risk factors for disease progression, was prematurely discontinued due to manifest superiority of the drug compared to placebo in reducing hospitalizations and deaths: in patients treated with Molnupinavir hospitalizations were 7.3% compared to 14.1% for placebo, while deaths were reduced to zero, against 8 cases (2.1 %) of the placebo group.

The centers that have been identified by Aifa for the administration of monoclonal antibodies are the same ones that can currently prescribe the drug, but given the characteristics of the patients to whom it can be administered.

– the deputy governor announced – the prescription will also be possible on the territory, subject to authorization to access the Aifa prescription.